Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10029-BC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10029-BC-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

XP_005591343

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all BCMA/TNFRSF17 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived BCMA/TNFRSF17 protein
Cynomolgus Monkey BCMA
(Met1-Ile54)
Accession # XP_005591343		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met1

Predicted Molecular Mass

33 kDa

SDS-PAGE

37-43 kDa, reducing conditions

Activity

Measured by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated mouse B cells. Moore, P.A. et al. (1999) Science 285:260; Gross, J.A. et al. (2000) Nature 404:995; Schneider, P. et al. (1999) J. Exp. Med. 189:1747.
The ED50 for this effect is 30-180 ng/mL.

Reviewed Applications

Read 1 review rated 5 using 10029-BC in the following applications:

Scientific Data Images for Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein, CF

Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein Bioactivity

Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein Bioactivity

Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Chimera (Catalog # 10029-BC) inhibits Recombinant Human APRIL/TNFSF13 (Catalog # 5860-AP) mediated proliferation of anti-IgM stimulated mouse B cells. The ED50 for this effect is 30-180 ng/mL.
Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein SDS-PAGE

Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein SDS-PAGE

2 μg/lane of Recombinant Cynomolgus Monkey BCMA/TNFRSF17 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 37-43 kDa and 75-85 kDa, respectively.

Formulation, Preparation and Storage

10029-BC
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: BCMA/TNFRSF17

BCMA, B cell maturation antigen, also known as Tumor Necrosis Factor Receptor Superfamily member 17 (gene name TNSFR17), is a member of the TNFR superfamily, due to the presence of its TNFR motif (1). BCMA is a type III membrane protein containing one extracellular cysteine rich domain, a transmembrane domain, and an intracellular domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily (2, 3). This binding to APRIL and BAFF has been shown to stimulate IgM production in peripheral B cells and increase the survival of cultured B cells (3, 4). This data suggests that BCMA may play an important role in B cell development, function and regulation (5). BCMA expression has been found in immune organs and mature B cell lines (5). Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment (6). Within the ECD, cynomolgus monkey BCMA shares 89% sequence identity with human BCMA, 62% with mouse BCMA, and 59% with rat BCMA. The expression of BCMA has also been linked to various cancers, autoimmune disorders, and infectious diseases (7). Proteolytic shedding of the BCMA extracellular domain generated soluble BCMA (sBCMA) via direct cleavage by gamma-secretase, elevated sBCMA levels in serum may correlate with disease activity (8). More recently, BCMA has been indicated as a possible biomarker in various human immunological disease, and as a potential therapeutic target for multiple myeloma (MM) (9-11).

References

  1. Hatzoglou, A. et al. (2000). J Immunol. 165:1322.
  2. Schiemann, B. et al. (2001). Science. 293:2111.
  3. Marsters, S.A. et al. (2000) Curr. Biol. 10:785.
  4. Huang, H. et al. (2013). PNAS. 110:10928.
  5. Laâbi, Y. et al. (1994). Nucleic Acids Res. 22:1147.
  6. Gras, M. et al. (1995) Int. Immunol. 7:1093.
  7. Coquery, C.M. et al. (2012) Crit Rev Immunol. 32:287.
  8. Laurent, S.A. et al. (2015) Nat Commun. 6:7333.
  9. Thaler, F.S. et al. (2017) Neuro Oncol. 19:1618.
  10. Seckinger, A. et al. (2017) Cancer Cell. 31:396.
  11. Lee, L. et al. (2018) Blood. 131:746.

Long Name

B Cell Maturation Factor

Alternate Names

CD269, TNFRSF13A, TNFRSF17

Entrez Gene IDs

608 (Human); 21935 (Mouse); 287034 (Rat); 102145399 (Cynomolgus Monkey)

Gene Symbol

TNFRSF17

UniProt

XP_005591343

Additional BCMA/TNFRSF17 Products

Product Documents for Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus/Rhesus Macaque BCMA Fc Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.